DE60204722D1 - Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten - Google Patents
Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheitenInfo
- Publication number
- DE60204722D1 DE60204722D1 DE60204722T DE60204722T DE60204722D1 DE 60204722 D1 DE60204722 D1 DE 60204722D1 DE 60204722 T DE60204722 T DE 60204722T DE 60204722 T DE60204722 T DE 60204722T DE 60204722 D1 DE60204722 D1 DE 60204722D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- treatment
- mediated diseases
- cell
- quinazoline derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0128108.8A GB0128108D0 (en) | 2001-11-23 | 2001-11-23 | Therapeutic use |
GB0128108 | 2001-11-23 | ||
PCT/GB2002/005222 WO2003045395A1 (en) | 2001-11-23 | 2002-11-20 | Quinazoline derivatives for the treatment of t cell mediated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60204722D1 true DE60204722D1 (de) | 2005-07-21 |
DE60204722T2 DE60204722T2 (de) | 2006-05-11 |
Family
ID=9926329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60204722T Expired - Lifetime DE60204722T2 (de) | 2001-11-23 | 2002-11-20 | Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten |
Country Status (7)
Country | Link |
---|---|
US (1) | US7160891B2 (de) |
EP (1) | EP1450808B8 (de) |
AT (1) | ATE297733T1 (de) |
AU (1) | AU2002343047A1 (de) |
DE (1) | DE60204722T2 (de) |
GB (1) | GB0128108D0 (de) |
WO (1) | WO2003045395A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0112969A (pt) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
PE20020958A1 (es) * | 2001-03-23 | 2002-11-14 | Bayer Corp | Inhibidores de la rho-quinasa |
AU2002250394A1 (en) * | 2001-03-23 | 2002-10-08 | Bayer Corporation | Rho-kinase inhibitors |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP1521747B1 (de) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Modulatoren von rezeptor-typ-kinase und anwendungsverfahren |
KR20120091266A (ko) | 2003-05-15 | 2012-08-17 | 디엠아이 바이오사이언시스, 인크 | T-세포 매개성 질환의 치료 방법 |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
KR20060100388A (ko) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
ATE532782T1 (de) | 2003-09-26 | 2011-11-15 | Exelixis Inc | C-met-modulatoren und anwendungsverfahren |
CA2545340A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
EP1833482A4 (de) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | Verbindungen und ihre therapeutische verwendung |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US20090221644A1 (en) * | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
US7869850B2 (en) * | 2005-09-29 | 2011-01-11 | Nellcor Puritan Bennett Llc | Medical sensor for reducing motion artifacts and technique for using the same |
US8073518B2 (en) | 2006-05-02 | 2011-12-06 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
KR20100111291A (ko) | 2008-02-07 | 2010-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법 |
CN102088979B (zh) | 2008-05-13 | 2013-10-16 | 阿斯利康(瑞典)有限公司 | 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-{[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]氧基}喹唑啉的富马酸盐 |
EP2300011A4 (de) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | Therapeutische verfahren und verbindungen |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
EA019959B1 (ru) | 2009-01-16 | 2014-07-30 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2012033792A2 (en) | 2010-09-07 | 2012-03-15 | Dmi Acquisition Corp. | Treatment of diseases |
CN102068434B (zh) * | 2011-01-25 | 2012-08-22 | 林治华 | 4-(环己基)-胺基喹唑啉类化合物的应用 |
BR112014007657A2 (pt) | 2011-10-10 | 2017-04-11 | Ampio Pharmaceuticals Inc | dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação |
JP6203734B2 (ja) | 2011-10-10 | 2017-09-27 | アンピオ ファーマシューティカルズ,インコーポレイテッド | 変形性関節疾患の治療 |
EA201490737A1 (ru) | 2011-10-28 | 2014-09-30 | Ампио Фармасьютикалз, Инк. | Лечение ринита |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
WO2014145729A2 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
RU2020136589A (ru) | 2014-08-18 | 2020-12-24 | Ампио Фармасьютикалз, Инк. | Лечение дегенеративных заболеваний суставов |
WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN107814793A (zh) * | 2017-12-30 | 2018-03-20 | 胡张艳 | 一种小分子Src酪氨酸激酶抑制剂塞卡替尼及其中间体的制备方法 |
CN107987064A (zh) * | 2017-12-30 | 2018-05-04 | 王兆举 | 一种治疗骨癌的药物塞卡替尼的制备方法 |
WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
CN108395410A (zh) * | 2018-05-09 | 2018-08-14 | 日照市普达医药科技有限公司 | 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用 |
CN114605273B (zh) * | 2022-03-29 | 2023-06-02 | 南昌航空大学 | 一种钯催化co参与的1,4-烯炔芳构化反应合成芳胺基酚类化合物的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CA2378291A1 (en) * | 1999-07-07 | 2001-01-18 | Astrazeneca Uk Limited | Quinazoline derivatives |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
-
2001
- 2001-11-23 GB GBGB0128108.8A patent/GB0128108D0/en not_active Ceased
-
2002
- 2002-11-20 WO PCT/GB2002/005222 patent/WO2003045395A1/en not_active Application Discontinuation
- 2002-11-20 EP EP02779708A patent/EP1450808B8/de not_active Expired - Lifetime
- 2002-11-20 US US10/496,587 patent/US7160891B2/en not_active Expired - Fee Related
- 2002-11-20 DE DE60204722T patent/DE60204722T2/de not_active Expired - Lifetime
- 2002-11-20 AT AT02779708T patent/ATE297733T1/de not_active IP Right Cessation
- 2002-11-20 AU AU2002343047A patent/AU2002343047A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1450808A1 (de) | 2004-09-01 |
GB0128108D0 (en) | 2002-01-16 |
US7160891B2 (en) | 2007-01-09 |
EP1450808B8 (de) | 2006-01-04 |
WO2003045395A1 (en) | 2003-06-05 |
AU2002343047A1 (en) | 2003-06-10 |
US20050038050A1 (en) | 2005-02-17 |
DE60204722T2 (de) | 2006-05-11 |
EP1450808B1 (de) | 2005-06-15 |
ATE297733T1 (de) | 2005-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE297733T1 (de) | Quinazolinderivate für die behandlung durch t- zellen vermittelter krankheiten | |
DE60319066D1 (de) | 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen | |
GB0226931D0 (en) | Chemical compounds | |
ATE487493T1 (de) | Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
WO2003049702A3 (en) | Vanilloid receptor ligands and their use in treatments | |
GB0209891D0 (en) | Novel compounds | |
EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
BR9809185A (pt) | Diidropiranos fundidos | |
DE60204951D1 (de) | Ccr5 antagonisten verwendbar für die behandlung von aids | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
NO20044549L (no) | Bisykliske 6-alkaliden-penemer som beta-laktamaseinhibitorer | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis | |
ATE352295T1 (de) | Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
WO2002074735A3 (de) | Biurethanderivate | |
UY27587A1 (es) | Heterociclos terapéuticos | |
DE50203154D1 (de) | Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen | |
DE60315597D1 (de) | Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen | |
DE60224805D1 (de) | 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un | |
ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |